The global hemophilia treatment market was estimated at USD 11.65 billion in 2017 and is expected to reach USD 15.85 billion in 2024 at a CAGR of 4.02% during the forecast period. Growing numbers of patients affected with hemophilia disease, and rising awareness about its diagnosis and treatment. However, high cost of therapy may inhibit the market growth. The years used for the assessment are as follows:

Historical year: 2014, 2015 and 2016

Base year: 2017

Forecast period: 2018 – 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources

Interacting with key opinion leaders of the market and developing data points based on interaction with them

Study of past trends in the market and their year on year impact on the market size and share

Analyzing the collected data points

Bridging the data points to calculate the total global hemophilia treatment market and its various segments

Anticipating potential risks

Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global hemophilia treatment market

Finalizing the overall size and share of the global hemophilia treatment market

Hemophilia Market: Major players are adopting strategies such as global expansion and product development, hence promoting growth of the market

Hemophilia is a rare bleeding disorder where one of the blood clotting factors is missing. There are two main types of hemophilia, hemophilia A, and hemophilia B. Hemophilia A is caused by deficient or dysfunctional clotting factor VIII, and hemophilia B due to factor IX deficiency. The deficiency or absence of one of these factors, may disrupt the blood clotting factor. People with bleeding disorders experience extended bleeding after trauma, injury, menstruation, and surgery.

Many major players focus on novel drug development in the treatment of hemophilia. Recently European Commission has approved Roche ‘’Hemlibra’’ for treatment of hemophilia A with factor VIII inhibitors. Japan’s Ministry of Health, Labor, and Welfare (MHLW) has approved CSL Behring’s “AFSTYLA” for the treatment of hemophilia A. Major players are investing in research and development activities for the development of novel drugs that can treat both types of hemophilia.

The treatment of hemophilia depends upon the type of hemophilia and the severity of hemophilia. Gene therapy is a novel approach to the treatment of hemophilia. In this treatment the gene is transferred through IV infusion and provides an individual with hemophilia a function FVIII or FIX gene. Major biotechnology and pharmaceutical companies focus on gene therapy for better treatment and increases the lifespan of patients with hemophilia.

North America held major market share of the global market in 2017. The growth in the region is attributed to growing number of people affected with hemophilia disease. According to the National Institutes of Health (NIH), approx 200,000 people suffered with hemophilia disease in the United States. Asia-Pacific region is expected to witness the fastest growth during the forecast period owing to growing number of drugs approval, and advancement in diagnostic technology.